Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-19 vaccine antibody response in kidney transplant recipients on tacrolimus + mycophenolic acid vs switch to mTOR inhibitor + low-dose tacrolimus
TCTR20220404001Phase 4Not yet recruiting
- Sponsor
- Chulalongkorn University
- Start
- Apr 2022
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tacrolimus, mycophenolic acid in coronavirus disease 2019 (COVID-19), kidney allograft rejection, sponsored by Chulalongkorn University. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
tacrolimusmycophenolic acid
03
Conditions
coronavirus disease 2019 (COVID-19)kidney allograft rejection
Beyond the preview
Go deeper on TCTR20220404001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220404001.